The leucine-rich repeat-containing protein 4 (LRRC4), also known as Netrin-G ligand-2 (NGL-2), is a transmembrane protein belonging to the leucine-rich repeat (LRR) superfamily. It plays a critical role in neural development, synaptic plasticity, and cell adhesion by mediating protein-protein interactions. LRRC4 is prominently expressed in the central nervous system, where it regulates axon guidance, neurite outgrowth, and the formation of excitatory synapses through interactions with netrin-G2 and other synaptic partners.
In cancer research, LRRC4 has been identified as a potential tumor suppressor, particularly in gliomas. Its downregulation or epigenetic silencing is associated with tumor progression, enhanced cell proliferation, and invasiveness. Studies suggest LRRC4 modulates signaling pathways like EGFR/ERK and Wnt/β-catenin, influencing oncogenic behaviors.
LRRC4 antibodies are essential tools for detecting LRRC4 expression in tissues or cell lines via techniques such as Western blotting, immunohistochemistry, or immunofluorescence. They aid in elucidating LRRC4's functional mechanisms in neurological disorders and cancer, offering insights into diagnostic biomarkers or therapeutic targets. Commercial LRRC4 antibodies are typically validated for specificity against human or model organism epitopes, supporting both basic and translational research. Ongoing studies continue to explore its dual roles in neurobiology and oncology.